Clade I, the culprit in the current 2025 version of global epidemic mpox, is highly transmissible and is spreading within ...

Tonix Pharmaceuticals (NASDAQ: TNXP) , a biopharmaceutical company developing innovative vaccines, is advancing TNX-801, a live, minimally replicatin ...

Canada has an opportunity to prevent sustained Clade I mpox transmission, but only if decisive action is taken now.

One dose of the Jynneos vaccine was 58% effective against mpox infection overall and 84% in people without HIV, but only 35% ...

NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, announced today the appointment of Retired United States Army ...

Universitätsmedizin Berlin has found that a single dose of the Imvanex vaccine provides protection against Mpox with 84% ...

Shares of GeoVax Labs, Inc. (NASDAQ:GOVX – Get Free Report) have received an average recommendation of “Buy” from the seven ...

After hours: March 18 at 4:05:05 PM EDT Loading Chart for GNLX ...

August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years ...

After hours: March 14 at 6:26:33 p.m. EDT Loading Chart for GNLX ...